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Abstract
Background: TP53 is an attractive candidate for modifying age of onset (AO) in Huntington
disease (HD): The amino-terminus of the mutated huntingtin (htt) exon 1 translation product has
functional properties which may affect critically the TP53 pathway in HD neurons. The pathogenic
domain of mutant htt interacts with nuclear transcription factors, and it potentially modulates
TP53-induced transcriptional events. A single nucleotide polymorphism (SNP) resulting in the R72P
exchange in TP53 protein might modulate the variation in AO. In addition, also the R196K
replacement in human caspase activated DNase (hCAD) may theoretically affect the AO.
Methods: We have genotyped the polymorphisms R72P and R196K in a well established cohort
of 167 unrelated HD patients.
Results: The expanded CAG repeat explained 30.8% of the variance in AO. Adding the genotypes
of the SNPs investigated did not affect the variance of the AO variance explained.
Conclusion: In this replication study, no association was found explaining a significant amount of
the variability in AO of HD thus contradicting a recent report.
Background
Huntington disease (HD) is an autosomal dominantly
transmitted, neurodegenerative disorder characterized by
motor abnormalities, cognitive dysfunction and psychiat-
ric symptoms [1]. HD is caused by an expansion of a pol-
yglutamine tract in the amino-terminal portion of the
protein huntingtin (htt), which apparently acquires a del-
eterious gain of function [2]. The length of the poly-
glutamine tract is the most important factor in
determining AO of HD, although substantial variability
remains after controlling for repeat length, particularly in
cases where CAG repeat numbers range in the high 30 s or
low 40 s [3]. Therefore, defining independent AO modify-
ing factors is of great importance, since they may provide
further clues pertaining to the pathology arising from the
expanded repeats. In mammals, TP53 is the most impor-
tant tumor suppressor gene. A variety of intracellular
stress signals activate TP53 to induce either transient cell
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cycle arrest with stimulation of repair activities, senes-
cence or apoptosis [4]. It has been proposed that the
amino-terminal portion of mutant htt encoded by exon 1
exertsfunctional properties with significant consequences
for the TP53 pathway in HD neurons. The pathogenic
domain of mutant htt interacts with critical transcription
factors and potentially modulates TP53-induced tran-
scriptional events [5]. It has been shown that the two var-
iations of the common codon 72 polymorphism (Arg /
Pro) in the TP53 gene differ with respect to the ability to
suppress cellular transformation [6] and induce apoptosis
[7]. Therefore, the R72P polymorphism represents a good
candidate for modulating the AO of HD. Recently this
polymorphism was described to explain a significant part
of the variance in the AO in HD [8]. In the same study also
the SNP R196K was investigated in the human caspase
activated DNase protein (hCAD), since DNase is responsi-
ble for DNA degradation during apoptosis [9]. Variations
in the latter SNP were likewise found to exert an addition-
ally significant impact on the variation of AO. We reinves-
tigated here whether TP53 and hCAD variations modulate
the AO of HD in our established cohort.
Methods
Our study population consists of 167 unrelated patients
with the clinical diagnosis of HD [10], recruited from the
Huntington Center (HZ) NRW, Bochum (Germany).
Clinical assessment and determination of the motor AO
was performed exclusively by two experienced neurolo-
gists/psychiatrists of the HZ NRW. Controls (healthy
blood donors from the German population of Essen)
were also genotyped for comparison. Informed consent
was obtained from all patients and controls. We pur-
posely selected a cohort with limited extent of CAG expan-
sions (41–45), since within this defined range the
expansions show linear correlation with AO. Within this
range ~75% of all elongated CAG alleles are comprised,
and they are distributed normally. CAG repeat sizes were
determined after PCR amplification of genomic DNA
from peripheral white blood cells. CAG repeats were
amplified by established methods [11]. The polymor-
phism R72P in the TP53 gene was demonstrated after PCR
amplification using the following primers: 5'-GAGGAC-
CTGGTCCTCTGACT-3' and 5'-GTAGGTTTTCTGGGAAG-
GGA-3'. PCR was carried out in a final volume of 10 µl
with 50 ng of DNA, 200 µM dNTP and 1 U Taq Polymer-
ase. Thermal cycling was performed with an initial dena-
turing step for 5 minutes at 94°C.; 35 cycles of
denaturation at 94°C for 1 min, annealing at 55°C for 1
min and extension at 72°C for 1 min; and a final exten-
sion at 72°C for 10 min. PCR products were digested with
the restriction enzyme Bsh1236I I at 37°C overnight and
visualised on 2% agarose gels stained with ethidium bro-
mide. This digestion yielded altogether 3 bands of differ-
ent sizes: a 254 bp fragment (restriction site absent)
corresponding to the C allele as well as a set of 160 and 94
bp fragments corresponding to the G allele (restriction
site present). The polymorphism R196K in the hCAD gene
was demonstrated using the following primers: 5'-CCTCT-
GACCACAGGACTGG-3' and 5'-TCTGTCGAAGTACGT-
GCCAT-3' under the same conditions mentioned above.
PCR products were digested with the restriction enzyme
Alu I at 37°C overnight. Digested DNA was electro-
phoresed on 3% agarose gels. The restriction fragments of
the G allele were 129, 99 and 13 bp in length. The A allele
harbors an additional restriction site so that the 99 bp
fragment is digested into 73 and 26 bp. The variability in
AO attributable to the CAG repeat number was calculated
by linear regression. For the regression analysis, we used
the AO as the dependent variable, the respective geno-
types as independent variables.
The CAG repeat number was considered as numerical var-
iables, the other putative modifying genotypes were con-
sidered as nominal variables. SPSS Ver.11.0 for Windows
(SPSS Inc.) was used for all statistical analyses.
Results and discussion
As detailed in an earlier study concerning our clinically
thoroughly characterised HD cohort, the expanded CAG
repeat explained 30.8% of the variance in AO [10]. Add-
ing the genotypes of the SNPs investigated here did not
affect the variance of the AO variance explained (Table 1).
Chattopadhyay et al. further conducted a case-control
study for these SNPs and found genotype GG in the TP53
gene to be a significant risk factor for HD. In order to retest
also this assumption, we performed a case-control study
as well. As expected, there was no difference between the
case and control groups. All frequencies observed were in
Hardy-Weinberg equilibrium and correspond to those
reported for the general Caucasian population [12].
Conclusion
Our study failed to replicate the association between the
genotypes at the R72P polymorphism in TP53 and R196K
polymorphism in hCAD genes with the AO of HD. Since
we employed a larger cohort of exceptionally well-charac-
terized HD patients the initial association may have been
due to chance or to bias as introduced by population strat-
ification. It is, however, possible that a true association
exists in Indians. The effect size may also be quite small,
requiring an even larger sample size than ours for
Caucasians.
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Table 1: Genotype frequencies and linear regression analysis of the SNPs in TP53 and hCAD genes
Gene Genotypes Number (%) Gene (polymorphism) R2 ∆R2 Unexplained 
variance (%)
p value
HD 
patients
Controls
TP53 GG 89 (53) 86 (51) HD CAG .308 -
CG 69 (41) 69 (41)
CC 9 (5) 13 (8) HD CAG +
TP53 (R72P) .314 .006 0.9 .130
hCAD GG 141 (84)
AG 23 (14) HD CAG +
AA 3 (2) hCAD (R196K) .305 .003 0.4 .590